Dopamine and Sensorimotor Function in Stuttering
University of California, San Francisco · with National Institute on Deafness and Other Communication Disorders (NIDCD), University of Washington · NCT07215884
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–65 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 1
- Target enrollment
- 25
- US sites recruiting
- 1
- Study start
- September 30, 2025
- Record last updated
- August 19, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of stuttering and possible interventions.
Being studied: Aripiprazole 10 MG; Placebo
Conditions: Stuttering, Adult
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- native speakers of American English
- for adults who stutter, presence of stuttering will be confirmed, with onset before age 6 years
- Normal hearing
- Ages of 18 to 65 years
- healthy adults without hearing-language difficulties
Exclusion Criteria
- self-reported speech-language-hearing difficulties other than stuttering
- self-reported neurological or psychological problems
- other medications (drugs that affect dopaminergic system and/or benzodiazepines)
Recruiting US locations
Biomagentic Imaging Lab
San Francisco, CA 94143
Site contact: Natalie Brunwin, MS · 415-476-6888 · snl-bil@ucsf.edu
Study contacts (from the official record)
- Natalie Brunwin, MS · 4154766888 · snl-bil@ucsf.edu
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55